Workflow
Immunome(IMNM) - 2024 Q3 - Quarterly Results
IMNMImmunome(IMNM)2024-11-13 21:06

Financial Position - As of September 30, 2024, Immunome reported cash, cash equivalents, and marketable securities totaling 240.1million,withacurrentcashrunwayexpectedtoextendinto2026[4].−TheaccumulateddeficitasofSeptember30,2024,was240.1 million, with a current cash runway expected to extend into 2026[4]. - The accumulated deficit as of September 30, 2024, was 435.5 million, an increase from 222.8millionattheendof2023[7].RevenueandExpenses−CollaborationrevenueforQ32024was222.8 million at the end of 2023[7]. Revenue and Expenses - Collaboration revenue for Q3 2024 was 2.9 million, down from 3.6millioninQ32023[8].−ResearchanddevelopmentexpensesforQ32024were3.6 million in Q3 2023[8]. - Research and development expenses for Q3 2024 were 37.2 million, including stock-based compensation costs of 1.8million[4].−In−processresearchanddevelopmentexpensesforQ32024were1.8 million[4]. - In-process research and development expenses for Q3 2024 were 6.7 million, related to business development activities[4]. - General and administrative expenses for Q3 2024 were 9.5million,includingstock−basedcompensationexpenseof9.5 million, including stock-based compensation expense of 3.1 million[4]. - Total operating expenses for Q3 2024 were 53.4million,significantlyhigherthan53.4 million, significantly higher than 8.2 million in Q3 2023[8]. Net Loss - Immunome reported a net loss of 47.1millionforQ32024,comparedtoanetlossof47.1 million for Q3 2024, compared to a net loss of 4.3 million for Q3 2023[8]. Clinical Development - Full enrollment for the Phase 3 RINGSIDE Part B study of AL102 was completed in February 2024, with topline data expected in the second half of 2025[3]. - Immunome anticipates submitting INDs for IM-1021 and IM-3050 in the first quarter of 2025[3].